Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| |
Authors: | Leonard Jeff Harris Kruti Patel Michael Martin |
| |
Affiliation: | 1.Oncology Division, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38103, USA; ;2.West Cancer Center & Research Institute, Memphis, TN 38103, USA; |
| |
Abstract: | The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL. |
| |
Keywords: | Relapsed or Refractory Diffuse Large B Cell Lymphoma DLBLC immunotherapy chemotherapy-free regimen |
|
|